Vertex’s Kidney Drug Cuts Proteinuria 52%, Heightens Novartis Fabhalta Competition
Vertex Pharmaceuticals’ RAINER study interim analysis showed povetacicept cut proteinuria by 52% from baseline and outperformed placebo by 49.8%, with all secondary endpoints met and no new safety signals. The promising data likely intensifies competition against Novartis’ Fabhalta in the IgA nephropathy market and could pressure Novartis’ share performance.
1. Vertex RAINER Study Results
Vertex released interim data for its phase III RAINER study in IgA nephropathy, showing a 52% reduction in proteinuria at 36 weeks and a 49.8% improvement over placebo, with all secondary endpoints met and a confirmed safety profile.
2. Competition with Novartis Fabhalta
Novartis’ Fabhalta, approved under accelerated review for reducing urinary protein in IgAN and also indicated for C3G and PNH, now faces heightened competition from povetacicept as Vertex prepares an expedited FDA submission.
3. Implications for Novartis
Vertex expects to complete its FDA filing for povetacicept by month-end using a priority review voucher to cut four months from review time, potentially enabling market entry that could erode Fabhalta sales and weigh on Novartis’ share performance.